NexgenRx Management

Management Kriterienprüfungen 2/4

NexgenRx's CEO ist Ron Loucks, ernannt in Mar 2003, hat eine Amtszeit von 21.17 Jahren. Die jährliche Gesamtvergütung beträgt CA$313.34K, bestehend aus 75% Gehalt und 25% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 10.34% der Aktien des Unternehmens, im Wert von CA$2.09M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7 Jahre bzw. 12.5 Jahre.

Wichtige Informationen

Ron Loucks

Geschäftsführender

CA$313.3k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	75.0%
Amtszeit als Geschäftsführer	21.3yrs
Eigentum des Geschäftsführers	10.5%
Durchschnittliche Amtszeit des Managements	7.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	12.7yrs

Jüngste Management Updates

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ron Loucks im Vergleich zu den Einnahmen von NexgenRx verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-CA$66k
Dec 31 2023	CA$313k	CA$235k	-CA$332k
Sep 30 2023	n/a	n/a	-CA$310k
Jun 30 2023	n/a	n/a	-CA$244k
Mar 31 2023	n/a	n/a	-CA$172k
Dec 31 2022	CA$287k	CA$235k	-CA$22k
Sep 30 2022	n/a	n/a	CA$3m
Jun 30 2022	n/a	n/a	CA$4m
Mar 31 2022	n/a	n/a	CA$4m
Dec 31 2021	CA$230k	CA$215k	CA$4m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$2m
Mar 31 2021	n/a	n/a	CA$2m
Dec 31 2020	CA$153k	CA$140k	CA$2m
Sep 30 2020	n/a	n/a	CA$1m
Jun 30 2020	n/a	n/a	CA$483k
Mar 31 2020	n/a	n/a	-CA$31k
Dec 31 2019	CA$181k	CA$165k	-CA$208k
Sep 30 2019	n/a	n/a	CA$38k
Jun 30 2019	n/a	n/a	-CA$147k
Mar 31 2019	n/a	n/a	-CA$438k
Dec 31 2018	CA$181k	CA$165k	-CA$697k
Sep 30 2018	n/a	n/a	-CA$1m
Jun 30 2018	n/a	n/a	-CA$1m
Mar 31 2018	n/a	n/a	-CA$793k
Dec 31 2017	CA$181k	CA$165k	-CA$626k

Vergütung im Vergleich zum Markt: RonDie Gesamtvergütung ($USD230.24K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Canadian ($USD176.35K).

Entschädigung vs. Einkommen: RonDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Ron Loucks (74 yo)

21.3yrs

Amtszeit

CA$313,342

Vergütung

Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ronald Loucks	Founder	21.3yrs	CA$313.34k	10.51% CA$ 2.2m
Kelly Elher	Chief Financial Officer	7.2yrs	CA$60.00k	0.63% CA$ 132.5k
Andrew Munroe	Senior Vice President of Pharma & Payor Partners	no data	CA$169.40k	keine Daten
Jason Robinson	Senior Vice President of Administration	no data	keine Daten	keine Daten
Doreen Harvey	Lead Human Resources	no data	keine Daten	keine Daten
Paul Bolger	Company Secretary	3.1yrs	keine Daten	keine Daten
Avik Debroy	Financial Controller	no data	keine Daten	keine Daten

7.2yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: Das Managementteam von NXG ist erfahren und erfahren (durchschnittliche Amtszeit: 7 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ronald Loucks	Founder	21.3yrs	CA$313.34k	10.51% CA$ 2.2m
Thomas Corcoran	Independent Chairman	18.3yrs	CA$30.00k	0.88% CA$ 184.5k
Charles Burns	Independent Director	7.1yrs	CA$22.50k	5.01% CA$ 1.0m
Randolf McGlynn	Independent Director	5.9yrs	CA$20.00k	0.14% CA$ 29.5k

12.7yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: NXGDie Vorstandsmitglieder sind sehr erfahren ( 12.5 ).

NexgenRx Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

NexgenRx Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

High number of new directors

Recent updates

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit